Summary: In this executive summary, our expert discusses how Catalent Cell & Gene Therapy continues to learn about formulating gene therapies by adapting methods used for other biologics.

Summary: In this on-demand webinar, our expert discusses how Catalent Cell and Gene Therapy is working towards an approach for gathering product knowledge and establishing formulation selection criteria using traditional/routine techniques as well as evaluating novel methodologies for gene therapy products.

Summary: Catalent offers tools to measure the ratio and help assess the safety and efficacy of viral vector-based therapies.

Summary: In this webinar, hear from Catalent panelists as they discuss navigating the path from research lab to the clinic.

Summary: Radiance® data is presented on rapid and low error adenovirus and baculovirus infectivity measurements as well as AAV transfection monitoring.

Summary: The successful outcomes delivered by cell and gene therapies coupled with emergence of modalities across nucleic acid therapeutics and microbiomes pose the next challenge for innovators to make these new modalities...

Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.

Summary: Catalent Cell & Gene Therapy is a premier partner for innovators across the entire field of advanced biotherapeutics. Explore our development and manufacturing capabilities for allogeneic and autologous cell therapies, viral vector-based...

Summary: In this on-demand webinar from the 2020 CPhI Festival of Pharma, panelists discuss innovative technologies and their adoption for cell and gene therapies.

Summary: Julien Meissonnier, Catalent’s Vice President and Chief Scientific Officer, discusses innovative approaches, technology disrupters, and more in this webinar.